Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022. The funding will push its lead program, a treatment based on a hallucinogenic compound found in ...

Two markets that have so far not been as extensively interconnected, but could soon be. Each goes at its own pace and touches on very distinct areas of human activity — or not as much? Psychedelics ...

Alcohol use disorder (AUD) has increased during the Covid-19 pandemic Conventional therapies for AUD have limited effectiveness in ensuring long-term remission and harm reduction Journey Colab will ...

In the final episode of our video series on the future of mental health care, SELF examines the therapeutic potential of psychedelics and what it could mean for the future of communal healing and ...